EP PerMed
European Partnership
for **Personalised Medicine**

Joint Transnational Call for Proposals (2026) for

Personalised Medicine for CARdiovascular, MEtabolic, and kidNey diseases (CARMEN2026)

(EP PerMed Grant 101137129)

Announcement

For further information, please visit our website: www.eppermed.eu

or contact the EP PerMed Joint Call Secretariat (JCS)

The French National Research Agency (ANR)
86 rue Regnault, 75013 Paris, FRANCE

Monika Frenzel
Phone: +33 01 73 54 83 32
Email: eppermed@agencerecherche.fr

Co-funded by the European Union

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101137129.

EP PerMed

European Partnership
for **Personalised Medicine**

Announcement for the Joint Transnational Call (JTC) 2026

The **European Partnership for Personalised Medicine, EP PerMed** (supported by the European Union under Horizon Europe, Grant Agreement N° 101137129), is a platform for joint programming of national and European regional research and innovation supporting activities putting into action "The Strategic Research & Innovation Agenda (SRIA) for Personalised Medicine (2023)", **SRIA for PM (2023)**, through dedicated research, development and innovation funding.

The EP PerMed funding organisations listed below have agreed to launch the joint transnational call 2026 (JTC2026) "Personalised Medicine for CARdiovascular, MEtabolic, and kidNey diseases" (acronym: CARMEN2026), co-funded by the European Union, to fund multinational, innovative research projects in personalised medicine (PM), which should bring together academic, clinical/public health and private research teams, thus enhancing the competitiveness in Europe and beyond in this field. The JTC2026 will be conducted simultaneously by the participating funding organisations in their respective region/country and coordinated centrally by the Joint Call Secretariat (JCS), hosted by the French National Research Agency, (ANR), FRANCE.

The call will be implemented in two stages, i.e. a pre- and a full proposal phase. The available budget for this call is **38 Mio. € (approx.)**.

Expected timeline of the call

25 November, 2025	Publication of the call
16 December, 2025	JTC2026-Information Day online webinar : Register here
26 January 2026, 23:00, CET)	**Deadline to complete the SAMRC Pre-eligibility Check form.**
10 February, 2026 (14:00, CET)	Deadline for pre-proposal submission to PT OUTLINE
Expected around 05 May, 2026	Communication of the results of the pre-proposal assessment and invitation to the full proposal stage
09 June, 2026 (14:00, CEST)	Deadline for full proposal submission
Mid/end of August 2026	Rebuttal stage
Expected for October 2026	Communication of the funding decisions to the applicants
End of 2026, beginning of 2027	Expected project start (according to regional/national funding regulations)

Co-funded by the European Union

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101137129.

EP PerMed
European Partnership
for **Personalised Medicine**

Information Day

An information day introducing the JTC2026 to the research community will be organised on 16 December 2025, 10:00 AM CET.

For more information and accessing the registration form: **https://www.eppermed.eu/news-events/events/ep-permed-jtc2026-information-day/**

Electronic submission website

Electronic proposal submission is mandatory on **PT-Outline**. Research project consortia who intend to submit a transnational proposal should register as soon as possible, by clicking on **"Sign up"** and follow further instructions.

Contact persons for the Joint Call Secretariat (JCS)

The **EP PerMed JCS** is hosted by the **French National Research Agency (ANR), France:**

Monika Frenzel
Phone: +33 01 73 54 83 32
Email: eppermed@agencerecherche.fr

EP PerMed Partnering Tool

The new partnering tool **https://www.b2match.com/e/eppermed-partnering** will open soon.

Call Documents

Depending on the country of origin, additional documents may be required:

All South African Applicants must complete the pre-eligibility check before submission of the joint application. This *SAMRC Pre-eligibility Check form must* ***be completed by South African Applicants***

Deadline to complete the SAMRC Pre-eligibility Check form is 26 January 2026.

The call text and all additional documents can be downloaded below:

- ***Call text* (PDF)**
- ***Guidelines for applicants* (PDF)**
- **Pre-proposal form (DOCX)**
- **Full-Proposal Form (DocX)**

Co-funded by
the European Union

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101137129.

EP PerMed
European Partnership
for **Personalised Medicine**

Aims of the Call

The overall objectives of the JTC2026 will be to

- Fund research projects in human health on innovative PM strategies for patients with cardiovascular, metabolic or kidney diseases. Research projects may focus on a single disease or explore these conditions in combination. Proposals should address one or more of the following aspects:
    - Development and validation of **innovative personalised therapeutic approaches** for cardiovascular, metabolic or kidney diseases through testing in relevant pre-clinical models (e.g., human cell cultures, organoids, organs-on-chips, disease-specific animal models, or in silico models).
    - Identification and validation of molecular markers/signatures or cutting-edge technologies (see also point 2 below) to **monitor treatment response** in patients with cardiovascular, metabolic or kidney diseases **in order to tailor treatment pathways**. This may include the analysis of the treatment effectiveness or treatment-related (including multi-medication) adverse effects as well as dose optimisation.
    - Identification and validation of stratifying molecular markers/signatures or stratifying diagnostic **technologies for early disease risk prediction and prevention of disease worsening or comorbidities** in patients with cardiovascular, metabolic or kidney diseases, thereby delaying the progression to cardiovascular-kidney-metabolic syndrome.
- Encourage and enable interdisciplinary collaborations, i.e. multi-actor research by engaging a range of other relevant disciplines such as pre-clinical and clinical research, bioinformatics/health informatics/data research, ELSA research, implementation research or health economics research connected to the proposed research topic, including end-user perspective analysis to support the implementation of the research outcomes into clinical practice.
- Encourage cross-sectorial collaborations, by including the private sector (e.g. SMEs, small and medium-sized enterprises), industry, as well as regulatory/HTA agencies and patient organisations.
- Establish participatory research, i.e. active representation of patients or citizens as part of research projects.

Research projects that combine a personalised medicine approach with care strategies targeting shared biological pathways or common underlying mechanisms of cardiovascular, metabolic and kidney diseases are welcome.

Projects are encouraged to **combine the following aspects** in their research:

1. Multi-omics data such as genomics, epigenomics, metagenomics, transcriptomics, proteomics and metabolomics data in relation to treatment outcomes. These data may be obtained from health data platforms or infrastructures, including population-level health databases.

Co-funded by
the European Union

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101137129.

2. Cutting-edge technologies such as AI/ML algorithms, next-generation imaging technologies, digital health tools, etc. to enhance early diagnosis, monitor treatment response, optimise therapy effectiveness or dosage, and detect or prevent comorbidities and treatment-related side effects in patients.
3. Information regarding patient medication, dose or compliance, medication efficacy, adverse effects, patient reported outcomes (PRO) or patient preferences.
4. Additional factors such as sex/gender dimension, age, environmental and social background, lifestyle, or nutritional status.

Participatory research should be established in that active representation of patients or citizens is part of research projects. EP PerMed is supporting this approach by providing dedicated funding to organisations representing patients or citizens to participate as partners in proposals submitted to this call. Those organisations could support in designing the research, ensuring that research questions are relevant from the patients' and citizens' point of view. They might also support in collecting data for PROs and adverse effects.

Projects funded under this call are furthermore **required to include a dedicated work package focussing on the question of the translation or implementation of the research outcomes into clinical practice** with a focus on e.g. patient outcome, patient preferences, costs, reimbursement, education (to healthcare providers, patients and citizens), ELSA (ethical, legal and societal aspect) or accessibility at the point of care.

Please refer to the Call Text of the JTC2026 for further information and definitions.

General (Eligibility) Conditions for Application

Joint research proposals may be submitted by applicants belonging to an entity according to the following categories (subject to regional/national funding regulations; see "Guidelines for Applicants"):

A. Academia (research teams working in universities, other higher education institutions) **or research institutes;**

B. Clinical/public health sector (research teams working in hospitals/public health and/or other healthcare settings and health organisations). Participation of clinicians (e.g. medical doctors, nurses), pharmacists and general practitioners in the research teams is encouraged;

C. Private for-profit (industry) partners, e.g. SME[1] (small and medium-sized enterprises) **and private non-profit partners**, e.g. foundations, associations or non-governmental organisations.

Consortia submitting applications to this call are **strongly encouraged to include partners from different categories (A, B and C)** in line with the crosscutting/multidisciplinary nature of the call, where the aim is to include partners at different levels in the value chain. It is also **strongly recommended to integrate at least one early-career researcher (ECR) as principal investigator** in a consortium (for the EP PerMed definition of ECR, please consult the Annex III of the "Call Text").

[1] https://ec.europa.eu/growth/smes/business-friendly-environment/sme-definition_en

Co-funded by the European Union

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101137129.

Only transnational projects will be funded. **Each consortium must involve at least three partners from three different EU Member States or Associated Countries whose funding organisations participate in the call. Each of these partners must be eligible and request funding from the respective funding organisation.** All three legal entities must be independent of each other**. The project coordinator must be eligible to be funded** by their regional/national participating funding organisation. The project coordinator (i.e. principal investigator and organisation) cannot be changed between the first and second stage.

Max. 2 project partners per consortium can request funding from the same funding organisation. For some funding organisations, the maximum number of eligible partners who can be funded in one project is limited to one (see also "Guidelines for Applicants" for individual funding rules).

No more than one partner on own funds is allowed in the consortia with at least three partners eligible for funding (more indications in the Call Text: "B. Funding recipients", section 7).

Pre-proposal stage: Maximum number of partners is 6 (no more than 2 partners from the same country including partners on own funds); Maximum number of partners can be 7 if the consortium includes a 3rd partner of the same country (condition: funding requested from at least 2 different funders of the respective country; applies to only one country per consortium; including partners on own funds).

Widening concept: Consortia are allowed to include in the **full proposal phase** an additional project partner that is eligible to receive funding from a funding organisation that is underrepresented in the second stage of the call and that agrees to participate in the widening option (a list of underrepresented regions/countries will be provided to coordinators invited to submit full proposals). The rules for the consortium composition need to be respected, i.e. the final number of partners can only sum up to 7 or 8 if there are 3 partners of the same country in a consortium (**condition**: funding requested from at least 2 different funders of the respective country; applies to only one country per consortium, including partners on own funds).

Exception: To facilitate the integration of organisations representing patients or citizens in consortia, they can be added as additional partners at the pre-proposal stage or full proposal stage. Organisations representing patients or citizens can be added as additional partner(s) either on own funds or by applying for funding, if eligible, from EP PerMed (see page 10 of the call text) or the respective funding organisations. The consortia must follow all of the above-mentioned rules regarding the consortia composition without counting the patient/citizen representing organisations, except for the following rule: **within one consortium, no more than 2 partners can request funding from the same funding organisation, including patient/citizen organisations.** For some funding organisations, the maximum number of eligible partners who can be funded in one project is one.

Each project partner has to be represented by **one principal investigator**. Within a joint proposal, each project partner's principal investigator will be the contact person for the JCS and the relevant regional/national funding organisation. Each consortium must nominate one **project coordinator** among the project's principal investigators. The nomination of a project co-coordinator is not allowed.

If a **partner** is found to be ineligible by one of the funding organisations after the formal check, the entire proposal may be rejected without further review. For a definition of eligible partners, see "Guidelines for

Co-funded by
the European Union

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101137129.

Applicants", the regional/national regulations, and contact the concerned regional/national funding organisation.

A maximum project duration of 3 years may be applied for.

Number of partners in the proposal*	**Pre-proposal**					**Full proposal** (only by inclusion of one underrepresented region/country)
	3	**4**	**5**	**6**	**7**	**+1**
Maximum number of partners with own funding**	0	1	1	1	1	1
Maximum number of partners per country***	1	2	2	2	3	3 (if the number of partners in the full proposal stage sums up to 7 or 8)

* minimum of three partners eligible for funding from three different EU Member States countries, or two EU Member States and at least one Associated Country whose funders participate. Patient/citizen representing organisations are not included in this calculation.

** patient/citizen representing organisations are not included in this calculation and can be added as partners participating with own funding at the pre- and full proposal stage.

*** maximum number of partners in the pre-proposal phase can be 7 if the consortium includes a 3rd partner of the same country (condition: funding requested from at least 2 different funders of the respective country; applies to only one country per consortium, including partners on own funds). Patient/citizen representing organisations are not included in this calculation and can be added as additional partners in the pre-proposal or full proposal stage. They can participate either on own funds or apply for funding, if eligible, from the regional/national funding organisation or EP PerMed. Please note: **within one consortium, not more than 2 partners can request funding from the same funding organisation, including patient/citizen organisations.** For some funding agencies, the maximum number of eligible partners who can be funded in one project is one.

All eligibility criteria and submission requirements are detailed in the following two call documents: "Call text" and the "Guidelines for Applicants".

Whilst applications will be submitted jointly by groups from several countries, individual groups will be funded by the individual EP PerMed funding organisation respective of the region/country from which applicants applies. The applications are therefore subject to eligibility criteria and regulations of individual funding organisations. Applicants are strongly advised to contact their regional/ national representatives of the participating relevant funding organisation as soon as possible in order to confirm their eligibility (see also below "*Contact list*").

Co-funded by the European Union

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101137129.

EP PerMed
European Partnership
for **Personalised Medicine**

SOUTH AFRICAN SPECIFIC GUIDELINES

Funding Organisation	**The South African Medical Research Council, (SAMRC)**
Initial funding pre-commitment	450.000 € (approx.) (R 9.200.000) Expected to fund 3 projects up to 150.000 € per project (excluding Value Added Tax (VAT) and including a 5% overhead cost)
Regional/National contact for the EP PerMed JTC2026	Rizwana Mia Senior Program Manager – Precision Medicine SAMRC- GRANTS INNOVATION & PRODUCT DEVELOPMENT Email: Rizwana.Mia@mrc.ac.za
Eligible institutions	South African universities, academic hospitals and other public or independent research organisations. This call will allow private entities to respond.
Additional eligibility criteria	Only South African citizens or permanent residents are eligible for SAMRC funding. Private non-profit or Private for-profit entities such as Small Medium Micro Enterprise's (SMME's) registered as a South African company under the Company's Act are eligible to apply. **https://www.gov.za/sites/default/files/gcis_document/201903/423041gon399.pdf** The company's SMME status must meet the requirements as stated by the definition of the South African National Small Enterprise Act, No. 102 of 1996. The eligibility criterion for a company to gain access to public entity funding is subject to meet the following requirements: i. Submit a valid CIPC company registration certificate and (Broad-Based-Black-Economic Equity (BBBEE) certification status ii. Submit a tax clearance certificate issued by the South African Revenue Service.

Co-funded by the European Union

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101137129.

	iii. Submit a financial status report (this should include a company balance sheet and financial income/ ex-pense statements), to show that its financial status is adequate to hold project funding and the entity fol-lows an audit process for usage and monitoring of funds. iv. The company directors may also be subject to a personal credit status check. A due diligence process will be executed to verify such information at the time of the award.
Eligible costs	Allowable costs include the following (all direct line items must be auditable): • Personnel: Soft-funded posts for individuals working on the project (e.g. post-docs, students, technicians, project managers) will be funded, provided an accurate estimation of time allocation is provided and they are not already funded from other means. • Consultants: These may include both local and/or foreign consultants who provide a service or capability that is not available among the project partners but is essential for the completion of project deliverables. • Equipment: Partial or full support for the cost of equipment may, in some instances, be requested, provided that it is directly required for the project. A budget limitation may apply. • Laboratory costs: consumables and other direct laboratory or research costs. • Sub-contracts: These may be to any local or international organization that provides a service or capability that is not available among the project partners but is essential for the completion of South African project deliverables. • Travel and accommodation that is directly related to the execution of the project. • Institutional overhead: An indirect costs rate of 5% is allowed. If research equipment is purchased using SAMRC funding, unless specified otherwise by the specific funding mech-anism, it becomes the property of the host institution. Under no circumstances may equipment become the prop-erty of the individual researcher to whom the funding was allocated. The equipment may not be removed from the host institution and/or transferred to another institution without the express written approval of the host institution and concurrence by the SAMRC. The institution must take responsibility for any necessary maintenance of and in- surance on the equipment.

Co-funded by
the European Union

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101137129.

	Budgets must be aligned to achievement of milestones and deliverables. The disbursement schedule will proceed with an upfront payment upon signature of the SAMRC funding agreement. Subsequent disbursements are subject to project progress based on achievement of milestones and deliverables, as well as adequate usage (up to 70%) of the previous disbursement.
Funding of public-private partnerships allowed	Yes, subject to the due diligence process stated above.
Further guidance	Non-allowable costs include the following: • Salaries of permanent or fixed term staff, e.g. tenured staff, professors etc., that are fully covered by the host institutions as well as permanent staff members from private entities. • Purchase or construction of a building. • Rental costs for space that is owned by the institutions/ private entities participating in the project. • Recruitment or retrenchment costs for staff. • Purchase of office furniture. The South African Applicant will have to complete separate annexures for the SAMRC Funding agreement. Annex-ure A- Adapted South African Project Proposal template and Annexure B -Project Budget template will be provided for completion upon award. These two annexures will be appended to the SAMRC Funding agreement and utilized to monitor and evaluate project progress. The SAMRC has a bi-annual reporting procedure. Each reporting period will be followed by the submission of pro-gress and finance reports. The SAMRC will adhere to annual funding disbursements. Private entities will be subje ct to six monthly disbursement schedules. For more detail on the general terms and conditions for SAMRC funding please refer to the SAMRC terms and con-ditions of funding, use the following link: Microsoft Word - SAMRC Terms and Conditions of Funding 2024 Clean Any publications press releases and other documents which include results obtained in the project must acknowledge the funding source as follows: “Research reported in this [publication/press release] was supported

Co-funded by the European Union

This project has received funding from the European Union’s Horizon Europe research and innovation programme under grant agreement No 101137129.

	by the South African Medical Research Council with funds received from the South African Department of Science and Innovation". Any publications that do not include this acknowledgement will not be accepted as outputs of the project. Requirements on data and repositories: The SAMRC strongly encourages open access to research outputs/data to be made available in recognized publicly available databases. The SAMRC conforms to Plan S -supported by cOAlition S, an international consortium of re-search funding and performing organisations. Plan S requires that, from 2021, scientific publications that result from research funded by public grants must be published in compliant Open Access journals or platforms. Regulatory and Ethical Compliance: All SAMRC grantees are required to obtain approval for any research involving human or animal subjects or samples therefrom the appropriate institutional review board or ethics committee and provide the SAMRC with a copy of such approval prior to undertaking the research. This requirement extends to all sites participating in the research. Any such research must, in addition to ethical approval compliance, be con-ducted in accordance with the generally accepted principles of "Good Clinical Practices", which shall include but not be limited to, requiring prior informed consent from the human subjects and shall be conducted in accordance with all applicable national and international regulations and guidelines pertaining to research involving human subjects, management of data confidentiality, research involving animals, use or release of genetically modified organisms, research use of recombinant DNA, and/or use of any organism, substance or material considered to be a biohazard, including adherence to all applicable standards for transport of specimens, both l ocally and interna-tionally, as appropriate. This also applies to the development of data repositories and the ongoing compliance to the Protection of Personal Information Act 4 of 2013. Compliance to South African Regulation: Ownership of any intellectual property (IP) and associated rights arising from SAMRC-funded projects (Foreground IP) shall be determined in accordance with the provisions of the Intellectual Property Rights from Publicly Financed Re-search and Development Act, 51 of 2008 and associated regulations as amended from time to time (IPR Act) and the institution's Intellectual Property Policy. The institution/ private entity is obliged to appropriately protect, manage, and commercialize the Foreground IP in accordance with all applicable provisions of the IPR Act and, in consultation with the SAMRC. The institution / Principal Investigator is required to report any

	Foreground IP devel-oped to the SAMRC as part of the reporting requirements. Project's processing/ handling any personal information will each comply with the provisions of the PROTECTION OF PERSONAL INFORMATION ACT 4 OF 2013 (POPIA). The institution/ private entity is obliged to appropriately protect and manage all personal information. Additional Partnership criteria applies to this call and requires you to complete the pre-eligibility check form https://redcap.link/Pre-EligibilityCheck-JTC2026

Contact details of participating members

The following countries (27) are participating in the preparation of the call: Austria*, Belgium, Czech Republic, Denmark, Estonia, Finland, France, Germany*, Greece, Hungary, Iceland, Ireland, Israel, Italy, Latvia, Lithuania, Luxembourg, Norway, Poland, Portugal, Romania, Slovak Republic, South Africa, Spain, Sweden, The Netherlands and Turkiye (contact list is provided below).

Five of the participating countries are represented by their specific regions (10): Flanders (Belgium), Wallonia-Brussels Federation (Belgium), Saxony (Germany)*, Lombardy (Italy), Tuscany (Italy), Azores (Portugal), Centro Region (Portugal), Andalusia (Spain), Catalonia (Spain) and Navarre (Spain).

**decision on participation is still pending*

For more information: **https://www.eppermed.eu/jtc2026/**

Contact list

Name of participating organisation	*Country/Region*	*Regional/National contact*
Austrian Science Fund, (FWF)*	Austria	Hannes Zwickl hannes.zwickl@fwf.ac.at Tel.: +43 676 83487 8219 Heike Höller heike.hoeller@fwf.ac.at Tel.: +43 676 83487 8220
The Research Foundation – Flanders, (FWO)	Belgium (Flanders)	Kristien Peeters (SBO) Tel.: +32 (0)2 550 15 95 Toon Monbaliu (FO) Tel.: +32 (0)2 550 15 70 europe@fwo.be
Fund for Scientific Research – FNRS, (F.R.S.-FNRS)	Belgium (Wallonia-Brussels Federation)	Maxime Bonsir maxime.bonsir@frs-fnrs.be Tel.: +32 2 504 92 36 Joël Groeneveld Tel.: +32 2 504 92 70 international@frs-fnrs.be
The Ministry of Health of the Czech Republic / Czech Health Research Council, (MZCR/AZVCR)	Czech Republic	Monika Kocmanova Monika.kocmanova@azvcr.cz Tel.: +420 778 973 186 Olga Laaksonen Olga.laaksonen@mzd.gov.cz Tel. : +420 604 786 141
Innovation Fund Denmark, (IFD)	Denmark	Rebecca Stiig Vibæk rebecca.stiig.vibaek@innofond.dk internationale@innofond.dk Tel.: +45 6190 5076
Estonian Research Council, (ETAG)	Estonia	Margit Suuroja Margit.Suuroja@etag.ee Tel.: +372 731 7360 Argo Soon Argo.Soon@etag.ee Tel.: +372 515 3424
Research Council of Finland, (AKA)	Finland	Rita Rinnankoski-Tuikka rita.rinnankoski-tuikka@aka.fi
Business Finland, (BFRK)	Finland	Norma Saha norma.saha@businessfinland.fi Tel.: +358 50 5577 012
Agence Nationale de la Recherche, (ANR)	France	Mylène Vaillancourt Tel.: (+33) (0) 1 78 09 80 36 Mérick Machouri Tel.: (+33) (0) 1 72 73 06 72 EPPerMed@agencerecherche.fr
Federal Ministry of Research, Technology and Space, (BMFTR) **German Aerospace Center e.V. – Project Management Agency, (DLR)**	Germany	Katja Kuhlmann Alexandra Becker permed@dlr.de Tel.: +49 228 3821-2211

Name of participating organisation	*Country/Region*	*Regional/National contact*
Federal Ministry of Health, (BMG) **German Aerospace Center e.V. – Project Management Agency, (DLR)**	Germany	Fabian Gondorf permed@dlr.de Tel.: +49 228 3821-2211
Saxon State Ministry for Science, Culture and Tourism, (SMWK)*	*Germany (Saxony)*	*Gabriele Süptitz* *gabriele.sueptitz@smwk.sachsen.de* *EuProNet@smwk.sachsen.de* *Tel.: +49 351 564-64210* *Caroline Karapanos* *caroline.karapanos@smwk.sachsen.de* *EuProNet@smwk.sachsen.de* *Tel.: +49 351 564-64220*
General Secretariat for Research & Innovation, (GRSI)	Greece	Foteini Karagkouni f.karagkouni@gsrt.gr Tel.: +30 213 1300132
National Research, Development and Innovation Office, (NKFIH)	Hungary	Zsuzsanna Kürti ncp@nkfih.gov.hu
The Icelandic Centre for Research, (RANNIS)	Iceland	Helga Snævarr Kristjánsdóttir Helga.s.kristjansdottir@rannis.is
Taighde Éireann-Research Ireland, (TE-RI)	Ireland	Emma McGrath Emma.mcgrath@researchireland.ie
Chief Scientist Office, Ministry of Health, (CSO-MOH)	Israel	Liron Even-Faitelson Liron.ef@moh.gov.il Tel.: +972-2-5082168
National Technological Innovation Authority, (IIA)	Israel	Sarah Chiche sarah.c@innovationisrael.org.il Tel.: +972 3 5118122
Italian Ministry of Health, (IT-MoH)	Italy	Maria Josefina Ruiz Alvarez mj.ruizalvarez-esterno@sanita.it Simona Carmen Ursu sc.ursu@sanita.it
Fondazione Regionale per la Ricerca Biomedica, (FRRB)	Italy (Lombardy)	Giulia Maria Rossignolo bandi@frrb.it Tel.: +39 0267650159
Tuscany Region, (RT)	Italy (Tuscany)	Donatella Tanini Tel.: +39 055 4383256 Teresa Vieri Tel.: +39 055 4383289 eppermed@regione.toscana.it
Latvian Council of Science, (LZP)	Latvia	Maija Bundule Maija.Bundule@lzp.gov.lv Tel: +371- 26514481 Uldis Berkis Uldis.Berkis@lzp.gov.lv Tel.: +371-29472349

Name of participating organisation	*Country/Region*	*Regional/National contact*
Research Council of Lithuania, (LMT)	Lithuania	Živilė Ruželė zivile.ruzele@lmt.lt Tel.: (+370) 676 14383
National Research Fund, (FNR)	Luxembourg	Gideon Gießelmann gideon.giesselmann@fnr.lu Tel.: +352 691 362 805
The Research Council of Norway, (RCN)	Norway	Karianne Solaas, kso@rcn.no Tel.: +47 945 35 380
National Centre for Research and Development, (NCBR)	Poland	Anna Stępień anna.stepien@ncbr.gov.pl Tel.: +48 22 39 07 210
Fundação para a Ciência e a Tecnologia, (FCT)	Portugal	Rita Cavaleiro Tel.: +351 213 911 541 Pedro Ferreira Tel.: +351 213 924 445 EPPerMed@fct.pt
Vice-Presidency of Azores Regional Government, (VP-GRA)	Portugal (Azores)	Maria Luís Adrião do Vale Maria.LA.Vale@azores.gov.pt Tel.: +351 296 308 922
Comissão de Coordenação e Desenvolvimento Regional do Centro, (CCDRC)	Portugal (Centro Region)	Sophie Patrício ccdrc.projects@ccdrc.pt Tel.: +351 239 400 100
Executive Agency for Higher Education, Research, Development and Innovation Funding, (UEFISCDI)	Romania	Nicoleta Dumitrache nicoleta.dumitrache@uefiscdi.ro Mihaela Manole mihaela.manole@uefiscdi.ro
Centrum vedecko-technických informácií Slovenskej republiky, (CVTI SR)	Slovak Republic	Magdaléna Švorcová magdalena.svorcova@cvtisr.sk Tel.: +421 917 733 493 Erika Jankajová erika.jankajova@cvtisr.sk Tel.: +421 904 859 228
The South African Medical Research Council, (SAMRC)	South Africa	Rizwana Mia Rizwana.Mia@mrc.ac.za Tel.: +27 21 938 0984
National Institute of Health Carlos III, (ISCIII)	Spain	Cándida Sánchez Barco eppermed@isciii.es
Consejería de Salud y Consumo de la Junta de Andalucía, (CSCJA)	Spain (Andalusia)	Alicia Milano Curto ep.fps@juntadeandalucia.es
Health Department – Generalitat de Catalunya, (DS-CAT)	Spain (Catalonia)	Montserrat Llavayol peris@gencat.cat Tel.: (+34) 935566103

Name of participating organisation	*Country/Region*	*Regional/National contact*
Government of Navarre, (CFN)	Spain (Navarre)	Javier Larrea flarreal@navarra.es Tel.: +34 848 42 76 47
Swedish Research Council, (SRC)	Sweden	Abraham Mellkvist-Roos Abraham.mellkvist-roos@vr.se Tel.: +46 76 525 7613
The Netherlands Organisation for Health Research and Development, (ZonMw)	The Netherlands	Rob Diemel Marcella de Boer EP-PerMed@zonmw.nl Tel.: +31 70 349 5252
The Scientific and Technological Research Council of Turkiye, (TUBITAK)	Turkiye	N. Selcan TÜRKER selcan.turker@tubitak.gov.tr Tel.: +90 312 298 1760

** Final decision for participation is still pending.*